You get it on every thread mate. Should you want to discuss...

You get it on every thread mate. Should you want to discuss anything objectively you often get shut down as a ramper. The results are somewhat of a vindication for dexamethasone. Not unexpected personally, but perhaps a surprise to the market (personally didn't know when they would hit). For those who are interested in competition (and as a treatment for COVID related ARDS it has to be considered that):

RESULTS A total of 299 patients (mean [SD] age, 61 [14] years; 37% women) were enrolled
and all completed follow-up. Patients randomized to the dexamethasone group had a mean
6.6 ventilator-free days (95% CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days
(95% CI, 2.9-5.4) in the standard care group (difference, 2.26; 95% CI, 0.2-4.38; P = .04). At
7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI, 5.5-6.7)
vs 7.5 (95% CI, 6.9-8.1) in the standard care group (difference, −1.16; 95% CI, −1.94 to −0.38;
P = .004). There was no significant difference in the prespecified secondary outcomes of
all-cause mortality at 28 days, ICU-free days during the first 28 days, mechanical ventilation
duration at 28 days, or the 6-point ordinal scale at 15 days. Thirty-three patients (21.9%) in
the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary
infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9
(6.1%) experienced other serious adverse events.

For me I am a little confused as why mortality wouldn't be the primary end-point. I suppose the trial is more about assisting ventilation in moderate to severe patients, a commendable endeavour. There is no significant difference on all-cause mortality. Can you post the one you are referring to?